A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  • STATUS
    Recruiting
  • End date
    Dec 19, 2023
  • participants needed
    1500
  • sponsor
    Eli Lilly and Company
Updated on 17 September 2021
Investigator
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Primary Contact
Kawartha Regional Memory Clinic (0.2 mi away) Contact
+394 other location
positron emission tomography
mini-mental state examination
alzheimer's disease
florbetapir
flortaucipir

Summary

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.

Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.

Details
Condition Dementia, Alzheimer's Disease, alzheimer, dementia alzheimer's type, Alzheimer Disease
Treatment Placebo, Donanemab
Clinical Study IdentifierNCT04437511
SponsorEli Lilly and Company
Last Modified on17 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Gradual and progressive change in memory function reported by participants or informants for 6 months
MMSE score of 20 to 28 (inclusive) at baseline
Meet 18F flortaucipir PET scan (central read) criteria - does not apply to safety cohort
Meet 18F florbetapir PET scan (central read) criteria
Have a study partner who will provide written informed consent to participate

Exclusion Criteria

Contraindication to MRI or PET scans
Current treatment with immunoglobulin G (IgG) therapy
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note